<DOC>
	<DOCNO>NCT00735826</DOCNO>
	<brief_summary>The primary aim study effect vorinostat cyclin E , cyclin D1 Ki-67 expression lung , bronchial epithelium , lung tumor patient resectable clinical stage I - III lung cancer . Secondary aim : To evaluate concentration vorinostat tumor tissue correlate lung tissue distribution plasma level patient ; perform exploratory analysis effect vorinostat induction apoptosis necrosis treat compare untreated tumor expression p21 , p27 , EGFR phospho-EGFR lung tumor patient resectable clinical stage I - III lung cancer ; perform dynamic contrast enhance CT primary tumor study effect treatment vascular supply tumor correlate result intratumoral vorinostat concentration .</brief_summary>
	<brief_title>A Clinical Trial Validate Molecular Targets Vorinostat Patients With Stage I-III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>All patient must pathological confirmation non small cell lung cancer . Patients must resectable clinical stage I III non small cell lung cancer define current International Staging System Lung Cancer . Age &gt; 18 year . Adequate hepatic renal function document prior study entry include : hepatic transaminase ( AST ALT ) ≤ 2.0 time upper limit normal , total bilirubin ≤ 1.5 time upper limit normal , serum creatinine ≤ 1.5 time upper limit normal estimate creatinine clearance ≥ 60 mL/min . All patient must medical candidate surgical resection nonsmall cell lung cancer . All patient must give informed consent indicate aware investigational nature treatment . Patients may receive radiation therapy nonsmall cell lung cancer . Patients may receive chemotherapy nonsmall cell lung cancer . Women must surgically sterilize postmenopausal woman childbearing potential must use adequate method contraception . Women childbearing potential must use least one following : oral , implanted , injectable contraceptive hormone , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) . Women childbearing potential must negative serum urine pregnancy test within 72 hour prior start study therapy . Women pregnant breastfeeding exclude . Male patient partner childbearing potential use adequate method birth control describe previous paragraph exclude . Patients gastrointestinal abnormality include : inability take oral medication , requirement intravenous alimentation , prior surgical procedure affect absorption exclude . A serious uncontrolled medical disorder active infection would impair ability receive study treatment exclude . Significant cardiac disease , include uncontrolled high blood pressure , unstable angina , congestive heart failure , myocardial infarction within previous 3 month serious cardiac arrythmias exclude . Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol exclude . Patients active HIV , HCV HCB infection . No prior treatment HDAC inhibitor . Valproic acid acceptable used anticancer therapy 30day washout period allow . Exposure investigational agent within 30 day study inclusion Patients `` currently active '' second malignancy , nonmelanoma skin cancer carcinoma situ cervix , enrol . Patients would consider `` currently active '' malignancy complete therapy prior malignancy , disease free prior malignancy &gt; 5 year consider physician less 30 % risk relapse . Patients history pulmonary embolism receive anticoagulation , exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>resectable</keyword>
	<keyword>stage I-III</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>vorinostat</keyword>
	<keyword>proof principle</keyword>
	<keyword>resectable stage I III NSCLC</keyword>
</DOC>